Advanced

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

Ashton, Nicholas J. ; Hye, Abdul ; Rajkumar, Anto P. ; Leuzy, Antoine LU ; Snowden, Stuart ; Suárez-Calvet, Marc ; Karikari, Thomas K. ; Schöll, Michael LU ; La Joie, Renaud and Rabinovici, Gil D. , et al. (2020) In Nature Reviews Neurology 16(5). p.265-284
Abstract

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-β, tau, phosphorylated tau and neurofilament light chain, are likely... (More)

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-β, tau, phosphorylated tau and neurofilament light chain, are likely to be relevant to other neurodegenerative disorders that involve similar pathological processes and could also be useful for the differential diagnosis of clinical symptoms. This Review outlines the neuropathological, clinical, molecular imaging and cerebrospinal fluid features of the most common neurodegenerative disorders outside the AD continuum and gives an overview of the current status of blood-based biomarkers for these disorders.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Reviews Neurology
volume
16
issue
5
pages
20 pages
publisher
Nature Publishing Group
external identifiers
  • pmid:32322100
  • scopus:85084051209
ISSN
1759-4758
DOI
10.1038/s41582-020-0348-0
language
English
LU publication?
yes
id
90330c72-6fb8-4c7b-a54b-02580c8cd85e
date added to LUP
2020-05-19 12:02:46
date last changed
2020-10-20 05:05:34
@article{90330c72-6fb8-4c7b-a54b-02580c8cd85e,
  abstract     = {<p>Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-β, tau, phosphorylated tau and neurofilament light chain, are likely to be relevant to other neurodegenerative disorders that involve similar pathological processes and could also be useful for the differential diagnosis of clinical symptoms. This Review outlines the neuropathological, clinical, molecular imaging and cerebrospinal fluid features of the most common neurodegenerative disorders outside the AD continuum and gives an overview of the current status of blood-based biomarkers for these disorders.</p>},
  author       = {Ashton, Nicholas J. and Hye, Abdul and Rajkumar, Anto P. and Leuzy, Antoine and Snowden, Stuart and Suárez-Calvet, Marc and Karikari, Thomas K. and Schöll, Michael and La Joie, Renaud and Rabinovici, Gil D. and Höglund, Kina and Ballard, Clive and Hortobágyi, Tibor and Svenningsson, Per and Blennow, Kaj and Zetterberg, Henrik and Aarsland, Dag},
  issn         = {1759-4758},
  language     = {eng},
  number       = {5},
  pages        = {265--284},
  publisher    = {Nature Publishing Group},
  series       = {Nature Reviews Neurology},
  title        = {An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders},
  url          = {http://dx.doi.org/10.1038/s41582-020-0348-0},
  doi          = {10.1038/s41582-020-0348-0},
  volume       = {16},
  year         = {2020},
}